Literature DB >> 12817878

Expression of the DNA mismatch repair proteins (hMLH1 and hMSH2) in infiltrating pancreatic cancer and its relation to some phenotypic features.

Romana Tomaszewska1, Krzysztof Okoń, Jerzy Stachura.   

Abstract

UNLABELLED: DNA mismatch repair system defects cause microsatellite instability (MSI) and form an alternative pathway in cancer development. Germline mutations of DNA mismatch repair genes account for hereditary nonpolyposis colorectal cancer, which has a different morphology and biology than sporadic cancers. MSI has also been found in sporadic neoplasms and some inflammatory conditions (chronic pancreatitis, ulcerative colitis). The purpose of the present study was to evaluate the expression of hMLH1 and hMLH2 proteins in infiltrating pancreatic cancer and to find out whether there is a relationship between some phenotypic manifestations and expression of MMR genes. We studied 30 cases of infiltrating pancreatic cancer and apart from hMLH1 and hMLH2 expression cytokeratin 7 and chromogranin were measured as markers of ductal and endocrine differentiation, respectively. All ductal pancreatic cancers expressed cytokeratin 7. In most cases the expression was strong, present in 50-100% of cells in moderately differentiated cancers and in 80-100% of cells in poorly differentiated cancers. Chromogranin expression was seen in 5 moderately differentiated cancers and in 6 poorly differentiated cancers (up to 20% of positive cells). In all cases DNA mismatch repair genes expression was present.
CONCLUSION: Ductal pancreatic carcinomas express hMLH1 and hMLH2 proteins irrespective of their differentiation. The expression of cytokeratin 7 is typical of ductal pancreatic carcinoma and its level is related to cancer differentiation. Some ductal pancreatic carcinomas irrespective of their differentiation show the expression of chromogranin, which is associated with the expression of hMSH2 gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817878

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  10 in total

1.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Authors:  Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

2.  Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer.

Authors:  M Li; Z W Zhao
Journal:  Med Oncol       Date:  2011-06-10       Impact factor: 3.064

3.  MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer.

Authors:  Wen-Jing Liu; Yu-Pei Zhao; Tai-Ping Zhang; Li Zhou; Quan-Cai Cui; Wei-Xun Zhou; Lei You; Ge Chen; Hong Shu
Journal:  J Gastrointest Surg       Date:  2013-05-29       Impact factor: 3.452

4.  Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.

Authors:  Yaacov R Lawrence; Jennifer Moughan; Anthony M Magliocco; Alexander C Klimowicz; William F Regine; Rex B Mowat; Thomas A DiPetrillo; William Small; Jeffry P Simko; Talia Golan; Kathryn A Winter; Chandan Guha; Christopher H Crane; Adam P Dicker
Journal:  Cancer       Date:  2017-10-20       Impact factor: 6.860

5.  Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

Authors:  Luigi Laghi; Stefania Beghelli; Antonino Spinelli; Paolo Bianchi; Gianluca Basso; Giuseppe Di Caro; Anna Brecht; Giuseppe Celesti; Giona Turri; Samantha Bersani; Guido Schumacher; Christoph Röcken; Ilona Gräntzdörffer; Massimo Roncalli; Alessandro Zerbi; Peter Neuhaus; Claudio Bassi; Marco Montorsi; Aldo Scarpa; Alberto Malesci
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

6.  Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line.

Authors:  Soon-Chan Kim; Young-Kyoung Shin; Sun-Whe Kim; Ha-Young Seo; Wooil Kwon; Hongbeom Kim; Youngmin Han; Ja-Oh Lee; Jin-Young Jang; Ja-Lok Ku
Journal:  Pancreas       Date:  2019 Nov/Dec       Impact factor: 3.327

Review 7.  Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.

Authors:  Michele Ghidini; Andrea Lampis; Milko B Mirchev; Ali Fuat Okuducu; Margherita Ratti; Nicola Valeri; Jens C Hahne
Journal:  Genes (Basel)       Date:  2020-12-29       Impact factor: 4.096

Review 8.  Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.

Authors:  Antonio Gnoni; Antonella Licchetta; Aldo Scarpa; Amalia Azzariti; Anna Elisabetta Brunetti; Gianni Simone; Patrizia Nardulli; Daniele Santini; Michele Aieta; Sabina Delcuratolo; Nicola Silvestris
Journal:  Int J Mol Sci       Date:  2013-09-30       Impact factor: 5.923

9.  MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.

Authors:  Christoph Fraune; Eike Burandt; Ronald Simon; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Martina Kluth; Franziska Büscheck; Doris Höflmayer; Niclas Ch Blessin; Tim Mandelkow; Wenchao Li; Daniel Perez; Jakob R Izbicki; Waldemar Wilczak; Guido Sauter; Jörg Schrader; Michael Neipp; Hamid Mofid; Thies Daniels; Christoph Isbert; Till S Clauditz; Stefan Steurer
Journal:  Ann Surg Oncol       Date:  2020-02-27       Impact factor: 4.339

10.  Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.

Authors:  Claudio Luchini; Lodewijk A A Brosens; Laura D Wood; Deyali Chatterjee; Jae Il Shin; Concetta Sciammarella; Giulia Fiadone; Giuseppe Malleo; Roberto Salvia; Valentyna Kryklyva; Maria L Piredda; Liang Cheng; Rita T Lawlor; Volkan Adsay; Aldo Scarpa
Journal:  Gut       Date:  2020-04-29       Impact factor: 31.793

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.